Abstract 2959: Novel CD38xCD3 bispecific IgM T cell engager, IGM-2644, potently kills multiple myeloma cells though complement and T cell dependent mechanisms
Keyu Li(Sichuan University), Bruce A. Keyt, Maya F. Kotturi(Alameda Hospital), Paul R. Hinton(IGM Biosciences (United States)), Mandy Li(IGM Biosciences (United States)), Stephen F. Carroll(IGM Biosciences (United States)), Gene Li(IGM Biosciences (United States)), Rodnie Rosete(IGM Biosciences (United States)), Dean Ng(IGM Biosciences (United States)), Umesh S. Muchhal(IGM Biosciences (United States)), Min Chai(IGM Biosciences (United States)), Poonam Yakkundi(IGM Biosciences (United States)), Angus M. Sinclair(LabGenius (United Kingdom)), Daniel Santos(IGM Biosciences (United States)), Thomas Manley(IGM Biosciences (United States)), Kevin C. Hart(Stanford University), Rui Yun(IGM Biosciences (United States)), Liqin Liu(Xinjiang Agricultural University)
Cited by 2
Related Papers
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock
|The Journal of Infectious Diseases|1999|611
Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution.
|Proceedings of the National Academy of Sciences|1986|518